Point72 Discloses 9.1% Stake in Aptevo (299,944 Shares)
Point72 entities and Steven A. Cohen disclosed beneficial ownership of 299,944 shares of Aptevo Therapeutics Inc. common stock, representing 9.1% of the class as of the close of business on September 16, 2025.
Rhea-AI Filing Summary
Point72 entities and Steven A. Cohen disclosed beneficial ownership of 299,944 shares of Aptevo Therapeutics Inc. common stock, representing 9.1% of the class as of the close of business on September 16, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through their management of Point72 Associates, while Mr. Cohen controls those entities. The statement includes a certification that the shares were not acquired to change or influence control of the issuer. The reporting parties executed a joint filing agreement (Exhibit 99.1) and provided principal business address information.
Positive
- Material stake disclosed: Reporting persons hold 299,944 shares, equal to 9.1% of Aptevo's common stock.
- Clear ownership chain: Filing explains that shares are held by Point72 Associates with investment and voting power held by Point72 Asset Management and control via Point72 Capital Advisors and Steven A. Cohen.
- Compliance and certification: Includes joint filing agreement (Exhibit 99.1) and a certification that the shares were not acquired to change or influence control.
Negative
- None.
Insights
TL;DR: Point72 group reports a 9.1% stake in APVO with shared voting/dispositive power; filing declares no intent to change control.
The Schedule 13G reports an aggregate position of 299,944 shares (9.1% of the class) held via Point72 Associates and managed by Point72 Asset Management, with Point72 Capital Advisors as general partner and Steven A. Cohen controlling those entities. The filing is consistent with passive investor disclosure under Rule 13d-1 and includes the required joint filing agreement. For investors, the disclosure confirms a material minority stake and identifies the parties with voting and disposition authority while stating the position is not intended to alter issuer control.
TL;DR: A well-structured 13G shows shared power among Point72 entities and a certification of passive intent.
The submission clarifies the ownership chain: Point72 Associates holds the shares, Point72 Asset Management maintains investment and voting power under an investment management agreement, Point72 Capital Advisors is the general partner, and Steven A. Cohen controls the entities. The filing includes the signature block and joint filing agreement reference, meeting formal disclosure requirements. The explicit certification that the securities were not acquired to influence control is an important compliance statement under the Exchange Act.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which Point72 entities are named in the Schedule 13G for APVO?
Does the filing state the Point72 group intends to change control of Aptevo?
What voting and dispositive powers are reported for the Point72 filers?
Where is the principal business address for the reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.